Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMSPBOW)

Drug Name

AIC100 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Thyroid cancer	2D10	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Intercellular adhesion molecule ICAM-1 (ICAM1)	TTCT6F7	ICAM1_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Intercellular adhesion molecule ICAM-1 (ICAM1)	DTT	ICAM1	7.993	5.81	6.662	5.926

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Thyroid cancer

ICD Disease Classification

2D10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Intercellular adhesion molecule ICAM-1 (ICAM1)	DTT	ICAM1	5.21E-01	0.38	0.32

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04420754) Study of AIC100 in Relapsed/Refractory Thyroid Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of AffyImmune Therapeutics.